Fujifilm applies for approval of Avigan as COVID-19 treatment in Japan

Credit: REUTERS/Kim Kyung Hoon

Fujifilm Holdings Corp said on Friday it had applied for approval in Japan of its anti-influenza drug Avigan as a treatment for COVID-19.

TOKYO, Oct 16 (Reuters) - Fujifilm Holdings Corp 4901.T said on Friday it had applied for approval in Japan of its anti-influenza drug Avigan as a treatment for COVID-19.

The company had said in September a late-stage study of Avigan had shown reduced recovery times for COVID-19 patients with non-severe symptoms and it would seek to file for approval as early as this month.

(Reporting by Chris Gallagher; Editing by Muralikumar Anantharaman)

((chris.gallagher@thomsonreuters.com;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More